Clinical Trial Update: Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating low-dose radiotherapy to enhance Pucotenlimab plus CAPEOX in mismatch repair-proficient locally advanced rectal cancer. The study is cu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Rectal Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• OXALIPLATIN (Oxaliplatin)
• Pucotenlimab

Snippet

Sponsor: Sun Yat-sen University | Conditions: Colorectal Cancer (CRC) | Phase 2 | Status: RECRUITING